Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. on January 17, 2019. The registrant is a Delaware corporation headquartered in Boston, Massachusetts. The filing serves as a Regulation FD disclosure regarding new clinical trial data.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure of clinical trial progress rather than financial performance.
Material Changes
The material event reported is the issuance of a press release announcing new data from the second cohort of the Phase 2 Clinical Trial for the company's drug candidate, ZGN-1061.
Guidance, Outlook, and Risks
Management Commentary: The company highlighted the release of new clinical data for ZGN-1061. The full details are contained in the press release furnished as Exhibit 99.1.
Legal Status of Information: The information in this report and the attached exhibit is intended to be "furnished" and is not deemed "filed" under Section 18 of the Exchange Act. It is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated.
Emerging Growth Company Status: The registrant is identified as an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Verify the specific clinical outcomes and safety data for ZGN-1061 in the press release (Exhibit 99.1) referenced in this filing.
- Confirm the current status of the Phase 2 trial and any subsequent regulatory milestones.
- Review the company's most recent 10-K or 10-Q for actual financial metrics, as this 8-K contains no financial data.
- Note the distinction that this information is "furnished" rather than "filed" for liability purposes.